Is MTLS a buy? — what our data shows
Materialise is a Belgian company that uses 3D printing — also called additive manufacturing — to make software, parts, and medical devices. Think of them as the company that helps hospitals print custom surgical guides and helps factories prototype new parts faster.
What our data shows
Our data on Materialise covers two things. First, the smart-money angle: 87 big investment funds report holding it, and the list includes some serious heavyweights — Berkshire Hathaway, Tiger Global, and Coatue. That's not nothing. Second, we tag Materialise under climate tech and genomics themes, which tells you where we think the long-term tailwinds are blowing. On the business side, the story is a bit of a split: their medical side is growing nicely — up over 15% — while their manufacturing side is shrinking. That tug-of-war is the key thing to watch. One honest note: our financial data coverage on this one is limited, so we're working with what the fund filings and our theme research tell us, not a full set of company financials.
The takeaway
Materialise is an interesting niche player with real institutional backing, but the business is at a crossroads between a growing medical arm and a struggling manufacturing side. The question worth asking is whether healthcare can carry the whole company forward.
Have your own question?
Ask in plain English — our data answers. Free for retail readers.
Ask a question →Informational research, not personalized investment advice.